Eyebright Medical released its 2026 half-year report. Net profit attributable to the parent in the first half was 183 million yuan, down 14.4% year on year. Operating revenue was 933 million yuan, up 18.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 177 million yuan, down 13.5% year on year. Net operating cash flow was 120 million yuan, down 22.0% year on year. Second-quarter operating revenue was 535 million yuan, up 24.5% year on year, while net profit attributable to the parent was 93.33 million yuan, down 22.7% year on year. The company continued to expand in areas such as intraocular lenses, orthokeratology lenses, and sports medicine. Total research and development spending was 71.78 million yuan, accounting for 7.70% of operating revenue.
Eyebright Medical Technology Beijing Co LtdNet profit attributable to parent fell 14.4% year on year despite revenue growth.
